Key Highlights

  • Tempest Therapeutics (NASDAQ:TPST) traded at USD 0.5400, up 5.84%, in pre-market trading on Tuesday, October 27, 2026, with no company-specific announcement dated on or just before that session to explain the advance.
  • For the quarter ended June 30, 2026, the company's release of Thursday, August 13, 2026 reported a net loss of USD 5.2 million, or USD 0.34 per share, against USD 7.9 million a year earlier.
  • Cash and equivalents stood at USD 0.8 million on June 30, 2026, compared with USD 7.7 million on December 31, 2025, and the year-end report cited a going concern risk and a need for additional capital.
  • The quote sits below USD 1.00 and reflects thin liquidity, so the price can change before the open at 9:30 a.m. ET.

The Pre-Market Move and Its Catalyst

Tempest Therapeutics (NASDAQ:TPST), a clinical-stage oncology company developing small molecules and an antibody-based asset, traded at USD 0.5400, up 5.84%, in pre-market trading on Tuesday, October 27, 2026, according to a pre-market snapshot. No company-specific announcement dated on or just before Tuesday, October 27, 2026 accompanied the move. The advance therefore appears consistent with thin pre-market liquidity, where few orders can shift the quote. The most recent company communication is the release of Thursday, August 13, 2026, which covered the quarter ended June 30, 2026. At USD 0.5400 the shares trade below USD 1.00, the level relevant to the Nasdaq minimum bid price requirement.

How the Latest Results Frame the Move

The company's release of Thursday, August 13, 2026 reported a net loss of USD 5.2 million, or USD 0.34 per share, for the quarter ended June 30, 2026, against USD 7.9 million, or USD 2.07 per share, a year earlier. Research and development expense was USD 1.8 million, down from USD 3.9 million, mainly because of lower spending after the February 2026 asset acquisition. General and administrative expense was USD 3.4 million, down from USD 4.1 million. Cash and equivalents were USD 0.8 million, against USD 7.7 million on December 31, 2025. The year-end report of Monday, March 30, 2026 cited a need for additional capital, so the balance sheet is the main influence on the share price.

Risks and What to Watch

The bull reading rests on pipeline milestones planned for 2026, including a potentially registrational study of TPST-2003 in relapsed or refractory multiple myeloma and first dosing of TPST-4003 in an investigator-initiated trial in China, expected in the fourth quarter of 2026. The bear reading rests on cash of USD 0.8 million against a quarterly net loss of USD 5.2 million, which implies a need for new financing. Named risks are dilution from any equity raise, Nasdaq minimum bid price compliance and reliance on partners for several programmes. Investors should watch the quarterly report for the period ending September 30, 2026, any financing announcement and the Federal Reserve decision on Wednesday, October 28, 2026.

Where Things Stand

The answer is that no company-specific announcement dated on or just before Tuesday, October 27, 2026 accompanied the 5.84% pre-market rise in Tempest Therapeutics (NASDAQ:TPST), which appears consistent with thin liquidity at a price of USD 0.5400. The key figure is cash of USD 0.8 million on June 30, 2026 against a quarterly net loss of USD 5.2 million. The next catalysts are the Federal Reserve decision on Wednesday, October 28, 2026, the fourth-quarter 2026 dosing of TPST-4003 in China and any financing update. Pre-market prices are snapshots and can change, and this is not investment advice.